GlassScriptPhysician profile
Anna M Malouf
NPI 1699115865
$1,101.15
in general payments reported to CMS, 2019-2025
13 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.38 · 2023: $393 · 2024: $335 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $440.44 | 2023-2025 | Stelara, Tremfya |
| Novo Nordisk INC | $124.99 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.46 | 2021-2024 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $101.57 | 2023 | Zeposia |
| Celgene Corporation | $84.00 | 2024 | Zeposia |
| Abbvie INC. | $43.32 | 2023-2024 | |
| Qol Medical, LLC | $39.18 | 2025 | Sucraid |
| Genzyme Corporation | $38.77 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $37.21 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $23.90 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $22.23 | 2025 | |
| Lucid Diagnostics INC. | $17.75 | 2025 | |
| Lilly USA, LLC | $15.33 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Malouf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.